Sabra Health Care REIT (SBRA)
NASDAQReal EstateReit - Healthcare FacilitiesSnapshot 2026-09-04
NASDAQReal EstateReit - Healthcare FacilitiesSnapshot 2026-09-04
Intact: The reason to own it still holds.
Sabra Health Care REIT grows revenue about 14% yearly, driven by portfolio growth. It maintains a stable dividend of $0.30 per share, showing strong capital allocation. Earnings per share are expected near $0.62 in 2026, supporting steady income. The company benefits from a stable healthcare real estate market.
Revenue growth could slow below 7% if healthcare demand weakens. Dividend cuts may occur if cash flow tightens. Earnings might miss guidance if operational challenges arise.
The current price reflects about 14% revenue growth and stable earnings near $0.62 per share in 2026. Our view aligns with these expectations but is more cautious than some analysts who expect higher earnings.
Breaks if: Dividend per share falls below $0.30 in any quarter of 2026
Breaks if: EPS guidance falls below $0.60 for FY26
Breaks if: YoY revenue growth falls below 7% next year
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This is a stable, long-term investment thesis focused on a real estate company. The company has demonstrated strong recent financial performance, but it operates in a sector facing headwinds, making the current thesis cautious.
The market currently prices SBRA at a premium compared to its peers, indicating that investors expect continued strong performance. However, there is a slight expectations gap, suggesting that the market may be anticipating some challenges ahead.
Management has shown strong execution with increased earnings guidance and revenue growth. However, there is a moderate risk of missing expectations, as the company has faced challenges in recent quarters.
The future performance of SBRA will depend on whether management can maintain or increase earnings guidance, the impact of potential Federal Reserve rate cuts, and the performance of sector peers like WELL, VTR, and DOC.
The most important moves since the prior daily snapshot.
No, our read on the company is unchanged. The recent financial performance remains strong. The signal changed from 'mild_favorable' to 'mixed', indicating a shift in sentiment. There are no new threats or supports impacting the thesis at this time.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
In the next 1 to 3 years, SBRA's performance will be influenced by its ability to navigate sector challenges and maintain growth. Not investment advice.